Form 4: Bioxytran Director Anders Utter Acquires Shares
SEC Form 4
Director Anders Utter acquired 266,955 shares of Bioxytran, Inc. at $0.114 per share on March 27, 2024.
Summary
- On March 27, 2024, Anders Utter, a director of Bioxytran, Inc., acquired 266,955 shares of the company's common stock.
- The purchase price was $0.114 per share.
- Following the transaction, Utter directly owns 874,576 shares of Bioxytran, Inc.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine transaction disclosure. The director's purchase could be interpreted as a positive sign, but it's not definitive.
Positives
- A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.
Industry Context
This transaction is a routine disclosure of insider trading activity. It is common for directors and officers of publicly traded companies to buy and sell shares of their company's stock. These transactions are closely monitored by regulators to prevent insider trading.
Stakeholder Impact
- The transaction could have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 03/27/2024 | Date of transaction: Anders Utter acquired 266,955 shares of Bioxytran, Inc. |
Keywords
Bioxytran, Anders Utter, Director, Share Acquisition, BIXT, Common Stock, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.